Welcome to our dedicated page for Prenetics Global SEC filings (Ticker: PRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Prenetics Global's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Prenetics Global's regulatory disclosures and financial reporting.
Prenetics Global Limited announced the appointment of Caroline Levy as an independent director to its Board, effective August 17, 2026. She will serve on the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, replacing Dr. Darshan Shah on those committees while he remains an independent director on the Board.
The company also highlighted its flagship brand IM8, described as the fastest-growing premium supplement brand, with over $200 million in annualized run-rate revenue achieved within 18 months of launch, shipping to 43 countries and delivering about 200,000 servings daily. Prenetics plans to report second quarter 2026 results on August 18, 2026, via a live webcast.
Prenetics Global Ltd reported an initial insider ownership filing for Tat Thuan Yen on a Form 3. Yen is identified as an officer, serving as VP, Finance of IM8 (US) LLC, an affiliated entity. The filing does not list any equity transactions or report any specific security holdings, and it includes an exhibit described as a Power of Attorney.
Prenetics Global Limited is registering up to 2,359,172 Class A Ordinary Shares for resale by existing holders of Class C “Exchange Warrants,” each exercisable for one share at $18.00. The company will not receive proceeds from share resales, only from any cash exercises of these warrants.
Prenetics is a Cayman Islands holding company with operations primarily in Hong Kong and other non‑mainland jurisdictions, focused on consumer health brands IM8 and CircleDNA. Recent portfolio actions include divesting its Europa 3PL logistics assets, selling its Insighta stake, and exiting digital assets, supported by detailed unaudited pro forma financials.
The company highlights legal and regulatory risks tied to operating in Hong Kong, potential future PRC oversight, and possible trading prohibitions under the Holding Foreign Companies Accountable Act if PCAOB access to Hong Kong auditors were again restricted.
Prenetics Global Limited entered into a growth financing arrangement for its IM8 business under a Customer Investment Agreement with GC Customer Value Arranger, LLC. Investors may fund up to an aggregate maximum of $1,000,000,000 for IM8’s sales and marketing growth efforts.
For each month, investors can fund up to 70% of IM8’s growth spend, and IM8 must remit a share of collections from customers first acquired in that month until an investor return cap is reached or 10 years elapse. The investor return cap per cohort is the lesser of an amount yielding a 30% internal rate of return across all cohorts in a year and a return multiple ranging from 1.035x to 1.170x of the Investment Amount. The commitment runs through and including August 11, 2028, and is guaranteed jointly and severally by IM8 Limited and Prenetics Limited.
Prenetics states that the structure is intended to deliver cash flow benefits to support IM8’s customer acquisition, but cautions that the impact of the arrangement is unpredictable and may not function as expected. Failure to achieve its objectives, or constraints on incurring additional indebtedness under related covenants, could materially and adversely affect its business, financial condition and results of operations, and the company may still require additional capital.
Prenetics Global Ltd director Hudson Blake Leogrande reported equity award activity. On August 4, 2026, 2,001 Restricted Stock Units that had vested on June 4, 2026 were settled into 2,001 Class A Ordinary Shares at an exercise price of $0.0000 per share. After these transactions, he directly held 4,001 Class A Ordinary Shares and 20,003 RSUs outstanding under the 2022 Share Incentive Plan.
Prenetics Global Limited, a Cayman Islands holding company with operations primarily in Hong Kong and other jurisdictions outside mainland China, files a second amendment to its 2025 annual report to revise key disclosures following SEC comments. The update clarifies its holding-company structure, cash flows within the group, non-IFRS metrics and Hong Kong/PRC-related risks.
The business generated all revenue outside mainland China and has two dormant PRC subsidiaries with no material assets. Management explains that, based on PRC counsel, current PRC approvals are not required, but future rule changes could affect operations and overseas listing. The company highlights HFCAA exposure but notes it was not a Commission-Identified Issuer for 2025 because its Hong Kong auditor is inspected by the PCAOB. It reports substantial net losses from 2023–2025, heavy marketing spend to grow CircleDNA and IM8, and significant internal cash transfers, while stating it has paid no dividends and does not plan near-term distributions. Prenetics also discloses holding approximately 510 Bitcoin as a long-term treasury asset, emphasizing valuation volatility and evolving regulatory and tax risks alongside broader operational, data, and governance risk factors.
Prenetics Global Limited closed a $1 billion growth financing arrangement with General Catalyst’s Customer Value Fund to scale its IM8 wellness brand. The facility can finance up to 70% of IM8’s marketing spend by monthly customer cohort, with General Catalyst receiving a capped share of cohort income until a fixed multiple is repaid.
No equity, warrants, or convertible instruments are issued, there is no fixed maturity or financial covenants, and recovery is limited to revenue from funded cohorts. The arrangement is classified as a financial liability, with the return component recorded as interest expense, leaving gross margin and operating expense classification unchanged. Prenetics reports approximately $139.7 million in combined cash, investments, and escrow and no debt as of May 31, 2026.
IM8 is described as the fastest-growing premium supplement brand, having delivered over 50 million servings and currently about 200,000 servings daily across 43 markets. IM8 generated preliminary unaudited June 2026 revenue of about $17 million, and FY 2026 IM8 revenue guidance has been raised to $210–220 million from $190–210 million. FY 2025 IM8 revenue was $60 million, and management expects IM8 to reach $300 million in annualized run-rate revenue by year-end 2026 and at least $400 million in 2027 revenue. Across 248,536 customers, every $1 of customer acquisition spend has generated $1.44 in cumulative gross profit on a blended basis.
Prenetics Global Ltd reported that officer Brian J. Rosin, CFO of IM8 (US) LLC, beneficially owns 56,851 Restricted Stock Units (RSUs) under the company’s 2022 Share Incentive Plan. Each RSU represents a contingent right to receive one Class A Ordinary Share, par value $0.0015 per share. Of these, 18,950 RSUs vest on May 14, 2027, another 18,950 RSUs vest in four equal tranches on August 14, 2027, November 14, 2027, February 14, 2028 and May 14, 2028, and the remaining 18,951 RSUs vest in four equal tranches on August 14, 2028, November 14, 2028, February 14, 2029 and May 14, 2029, in each case subject to continued service. Upon vesting, the RSUs are settled and delivered in shares at an exercise price of $0.0000 per share.
Prenetics Global Ltd director Hudson Blake Leogrande acquired 2,000 Class A Ordinary Shares through the settlement of vested Restricted Stock Units. These RSUs were granted under the company’s 2022 Share Incentive Plan and each unit converts into one Class A Ordinary Share.
After the transaction, Leogrande directly holds 2,000 Class A Ordinary Shares, while 22,004 Restricted Stock Units remain outstanding. The vesting and settlement reflect routine equity compensation rather than open-market buying or selling.
Prenetics Global Limited filed an amended annual report to add audited 2025 financial statements for its equity‑method investee Insighta Holdings Limited, after determining Insighta was significant under SEC Regulation S‑X Rule 3‑09.
Insighta reported 2025 revenue of HK$573,247, up from HK$244,218 in 2024, mainly from diagnostics services and laboratory testing kits. Profit for the year rose to HK$5,804,192, helped by other income of HK$27,896,174, largely bank interest. As of December 31, 2025, Insighta held HK$561.2 million in bank deposits with more than three months to maturity and HK$61.0 million in cash and cash equivalents, against total liabilities of only HK$6.5 million. Total assets were HK$636.1 million and equity HK$629.6 million, with no income tax expense recorded for the year.